Loading

Please wait...

Triumeq

Generic Name: abacavir, dolutegravir, and lamivudine (a BAK a vir, DOE loo TEG ra vir, la MIV ue deen)
Brand Names: Triumeq
Triumeq (abacavir, dolutegravir and lamivudine) is used to treat HIV-1 Infection. Includes Triumeq side effects, interactions and indications.
  • Prescription Settings
  • X
  • Local Pharmacy Pickup available at . Pick up your medication at any of our participating pharmacies.
  • Mail Order Home Delivery available at , the easiest way to receive your medications.
  • Learn more

Triumeq Coupons & Prices

Set your location
for drug prices near you

Enter your zip code

Please wait while the prices are loaded...
Click here to try again.

Don’t see your pharmacy listed? Most pharmacies accept our discounts, so have your pharmacist enter this coupon to see if you will save money:

Drug Information:
Triumeq contain a combination of abacavir, dolutegravir, and Lamivudine. Abacavir, dolutegravir, and Lamivudine are antiviral medications that prevent human immunodeficiency virus (HIV) from multiplying in your body. Triumeq is used to treat HIV, the virus that can cause acquired immunodeficiency syndrome (AIDS). This medicine is not a cure for HIV or AIDS. Triumeq is for use in adults and children who weigh at least 88 pounds (40 kilograms). You should not use Triumeq if you have moderate or severe liver disease, or if you are also taking Dofetilide (Tikosyn). Learn more

Pickup / Home Delivery

USARx offers multiple ways to purchase this medication. Choose the Best option for you!

  • Guaranteed Price
    Local Pharmacy Pickup

    Pay this amount and pick up your prescription at ANY Retail pharmacy of your choice! Walgreens, CVS, Walmart, etc.

  • 30-day supply
    90-day supply
    Mail Order Home Delivery

    The easiest way to receive your medications.

Triumeq Side Effects

Note: This document contains side effect information about abacavir / dolutegravir / lamivudine. Some of the dosage forms listed on this page may not apply to the brand name Triumeq.

For the Consumer

Applies to abacavir / dolutegravir / lamivudine: oral tablet

Warning

Oral route (Tablet)

Serious and fatal hypersensitivity reactions have been reported with abacavir; discontinue if hypersensitivity reaction suspected; never restart an abacavir-containing product after hypersensitivity reaction as potentially fatal reactions may recur within hours. Patients with HLA-B*5701 allele have a higher risk for abacavir-related hypersensitivity; screening for allele is recommended prior to initiating or reinitiation of therapy unless previous allele assessment is documented. Use is contraindicated in those with the HLA-B*5701 allele or with a previous hypersensitivity reaction to abacavir. Severe acute exacerbations of hepatitis B have been reported in patients co-infected with HBV and HIV-1 who have discontinued lamivudine; monitor hepatic function closely for several months upon discontinuation of therapy; initiation of anti-HBV therapy may be needed.

Along with its needed effects, abacavir/dolutegravir/lamivudine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking abacavir / dolutegravir / lamivudine:

Less common

  • Changes in weight
  • dark or bloody urine
  • decreased frequency or amount of urine
  • fever
  • general tiredness and weakness
  • increased blood pressure
  • increased thirst
  • itching skin
  • light-colored stools
  • loss of appetite
  • lower back or side pain
  • nausea
  • stomach discomfort, upset, or pain
  • swelling of the face, fingers, or lower legs
  • troubled breathing
  • unusual drowsiness, dullness, or feeling of sluggishness
  • unusual tiredness or weakness
  • upper right abdominal or stomach pain
  • vomiting
  • yellow eyes and skin

Rare

  • Rash

Incidence not known

  • Blistering, peeling, or loosening of the skin
  • blurred vision
  • burning, crawling, itching, numbness, prickling, "pins and needles", or tingling feelings
  • burning, dry, or itching eyes
  • chills
  • confusion
  • cough
  • decreased appetite
  • diarrhea
  • difficulty with moving
  • difficulty with swallowing
  • discharge or excessive tearing
  • dizziness
  • dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position
  • fainting
  • fast heartbeat
  • fast, shallow breathing
  • general feeling of discomfort or illness
  • headache
  • hives
  • joint or muscle pain
  • large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or genitals
  • muscle pain, cramping, or stiffness
  • puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue
  • rapid, shallow breathing
  • red, irritated eyes
  • redness, pain, swelling of the eye, eyelid, or inner lining of the eyelid
  • sleepiness
  • sore throat
  • sores, ulcers, or white spots in the mouth or on the lips
  • stomach pain, continuing
  • sweating
  • swelling or puffiness of the face
  • swollen, painful, or tender lymph glands in the neck, armpit, or groin
  • tightness in the chest

Some side effects of abacavir / dolutegravir / lamivudine may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

Less common

  • Belching
  • discouragement
  • excess air or gas in the stomach or bowels
  • feeling sad or empty
  • full or bloated feeling
  • heartburn
  • indigestion
  • irritability
  • loss of interest or pleasure
  • passing gas
  • pressure in the stomach
  • swelling of the abdominal or stomach area
  • thoughts or attempts of killing oneself
  • trouble concentrating
  • trouble sleeping

Rare

  • Abnormal dreams

Incidence not known

  • Anxiety
  • hair loss
  • thinning of the hair
  • weight gain around your neck, upper back, breast, or waist

For Healthcare Professionals

Applies to abacavir / dolutegravir / lamivudine: oral tablet

General

The most common side effects were insomnia, headache, fatigue, nausea, and dizziness.

Many of the side effects listed occurred commonly in patients with abacavir hypersensitivity (e.g., nausea, vomiting, diarrhea, fever, lethargy, rash).

Hypersensitivity

Hypersensitivity reactions were reported with abacavir and dolutegravir and shared some common features (e.g., fever and/or rash with other symptoms that indicated multi-organ involvement). In general, time to onset was 10 to 14 days for both abacavir- and dolutegravir-associated reactions.

Serious and sometimes fatal hypersensitivity reactions have been reported with abacavir. Such reactions have included multi-organ failure and anaphylaxis and usually occurred within the first 6 weeks of abacavir therapy; however, abacavir hypersensitivity reactions have occurred any time during therapy.

Patients with the human leukocyte antigen subtype B*5701 (HLA-B*5701) allele are at higher risk of abacavir hypersensitivity reactions; however, such reactions have occurred in patients without the HLA-B*5701 allele. Abacavir hypersensitivity was reported in about 8% of patients in 9 clinical trials with abacavir-containing products where patients were not screened for the HLA-B*5701 allele; incidence of suspected abacavir hypersensitivity reactions was 1% in clinical trials where HLA-B*5701 carriers were excluded.

Abacavir hypersensitivity reactions have been characterized by at least 2 of the following key signs/symptoms: (1) fever; (2) rash; (3) gastrointestinal symptoms (including nausea, vomiting, diarrhea, abdominal pain); (4) constitutional symptoms (including generalized malaise, fatigue, achiness); (5) respiratory symptoms (including dyspnea, cough, pharyngitis). Almost all reactions have included fever and/or rash (usually maculopapular or urticarial); however, reactions also reported without fever or rash. Signs/symptoms reported in at least 10% of patients with hypersensitivity reaction have included rash, nausea, vomiting, diarrhea, abdominal pain, dyspnea, cough, fever, fatigue/lethargy, malaise, headache, elevated liver function tests, and myalgia. Other signs/symptoms of hypersensitivity have included mouth ulceration, sore throat, adult respiratory distress syndrome, respiratory failure, edema, lymphadenopathy, hypotension, conjunctivitis, anaphylaxis, paresthesia, lymphopenia, hepatitis, liver failure, myolysis, arthralgia, elevated creatine phosphokinase, elevated creatinine, renal failure, abnormal chest x-ray findings (mainly infiltrates, which were localized), and death.

Symptoms of abacavir hypersensitivity reaction worsened with continued therapy and generally resolved when abacavir was discontinued. Restarting abacavir after a hypersensitivity reaction has resulted in more severe symptoms within hours and included life-threatening hypotension and death. Rarely, life-threatening reactions have occurred within hours after restarting abacavir in patients who stopped it for reasons other than symptoms of hypersensitivity (or who stopped it with only 1 key symptom of hypersensitivity).

Common (1% to 10%): Hypersensitivity

Frequency not reported: Hypersensitivity reaction (with rash and severe liver effects)

Abacavir, dolutegravir, and/or lamivudine:

-Postmarketing reports: Sensitization reactions (including anaphylaxis)

Abacavir:

-Common (1% to 10%): Hypersensitivity reactions (including fever, rash [maculopapular, urticarial], generalized malaise, fatigue, achiness, nausea, vomiting, diarrhea, abdominal pain, pharyngitis, dyspnea, cough, lethargy, headache, myalgia, myolysis, edema, abnormal chest x-ray findings [mainly localized infiltrates], arthralgia, paresthesia, anaphylaxis, hepatitis, liver failure, renal failure, hypotension, sore throat, adult respiratory distress syndrome, respiratory failure, death, lymphadenopathy, mucous membrane lesions [conjunctivitis, mouth ulcerations], erythema multiforme, elevated liver function tests, elevated creatine phosphokinase, elevated creatinine, lymphopenia)

Dolutegravir:

-Frequency not reported: Hypersensitivity reactions (characterized by rash, constitutional findings, and sometimes organ dysfunction, including liver injury)

Hepatic

Grade 2 and grade 3 to 4 elevations in AST were reported in up to 3% and up to 1% of therapy-naive patients, respectively. Grade 2 and grade 3 to 4 elevations in ALT were reported in up to 3% and up to 1% of therapy-naive patients, respectively. In general, laboratory abnormalities were similar in therapy-experienced patients.

The rates of AST and ALT abnormalities were higher in patients coinfected with hepatitis B and/or C virus (HBV and/or HCV). ALT abnormalities (grade 2 to 4) were reported in 15% and 2% of HIV/HCV-coinfected patients and HIV-monoinfected patients, respectively.

Lactic acidosis and severe hepatomegaly with steatosis (including fatal cases) have been reported with the use of nucleoside analogs.

Transaminase elevations were consistent with immune reconstitution syndrome or hepatitis B reactivation in some patients with underlying hepatitis B and/or C, especially when antihepatitis therapy was stopped.

Hepatic decompensation (some fatal) has been reported in patients coinfected with HIV-1 and HCV receiving combination antiretroviral therapy for HIV-1 and interferon alfa with or without ribavirin.

Severe acute exacerbations of hepatitis have been reported in patients with hepatitis B after discontinuation of lamivudine.

Very common (10% or more): ALT abnormalities (up to 15%)

Common (1% to 10%): Elevated AST, elevated ALT, AST abnormalities

Uncommon (0.1% to 1%): Hepatitis

Frequency not reported: Drug-induced liver injury leading to liver transplant

Postmarketing reports: Acute liver failure

Abacavir, dolutegravir, and/or lamivudine:

-Frequency not reported: Liver function test abnormalities, severe hepatomegaly with steatosis

-Postmarketing reports: Acute liver failure, liver transplant

Abacavir:

-Frequency not reported: Liver function test abnormalities, elevated liver chemistries (AST, ALT, alkaline phosphatase, bilirubin)

Dolutegravir:

-Frequency not reported: Transaminase elevations (consistent with immune reconstitution syndrome or hepatitis B reactivation), hepatic toxicity (including elevated serum liver biochemistries, hepatitis, acute liver failure)

Lamivudine:

-Frequency not reported: Elevated bilirubin, hepatic decompensation, severe acute exacerbations of hepatitis

Gastrointestinal

Grade 2 and grade 3 to 4 elevations in lipase were reported in up to 11% and up to 5% of therapy-naive patients, respectively. In general, laboratory abnormalities were similar in therapy-experienced patients.

Very common (10% or more): Nausea, diarrhea, elevated lipase

Common (1% to 10%): Abdominal pain, abdominal distention, abdominal discomfort, dyspepsia, flatulence, gastroesophageal reflux disease, upper abdominal pain, vomiting

Rare (0.01% to 0.1%): Pancreatitis

Abacavir, dolutegravir, and/or lamivudine:

-Postmarketing reports: Stomatitis, pancreatitis

Abacavir:

-Postmarketing reports: Pancreatitis

Lamivudine:

-Frequency not reported: Elevated lipase

-Postmarketing reports: Elevated amylase, pancreatitis

Psychiatric

Suicidal ideation, attempt, behavior, and completion have been reported, mainly in patients with history of depression or other psychiatric illness.

Very common (10% or more): Insomnia

Common (1% to 10%): Depression, abnormal dreams, nightmare, sleep disorder

Uncommon (0.1% to 1%): Suicidal ideation, suicide attempt

Frequency not reported: Suicidal behavior, suicide completion

Abacavir, dolutegravir, and/or lamivudine:

-Postmarketing reports: Anxiety

Dolutegravir:

-Postmarketing reports: Anxiety

Nervous system

Very common (10% or more): Headache

Common (1% to 10%): Dizziness, somnolence, lethargy

Abacavir, dolutegravir, and/or lamivudine:

-Postmarketing reports: Paresthesia, peripheral neuropathy, seizures

Lamivudine:

-Postmarketing reports: Paresthesia, peripheral neuropathy

Other

Very common (10% or more): Fatigue

Common (1% to 10%): Fever, asthenia, malaise

Frequency not reported: Fasted lipid values increased (including cholesterol, high-density lipoprotein [HDL] cholesterol, low-density lipoprotein [LDL] cholesterol, triglycerides)

Abacavir, dolutegravir, and/or lamivudine:

-Postmarketing reports: Weakness

Dolutegravir:

-Postmarketing reports: Increased weight

Antiretroviral therapy:

-Frequency not reported: Increased weight, increased blood lipid levels

Metabolic

Grade 2 and grade 3 hyperglycemia were reported in up to 9% and up to 2% of therapy-naive patients, respectively. In general, laboratory abnormalities were similar in therapy-experienced patients.

Lactic acidosis and severe hepatomegaly with steatosis (including fatal cases) have been reported with the use of nucleoside analogs.

Common (1% to 10%): Hyperglycemia

Uncommon (0.1% to 1%): Hypertriglyceridemia

Frequency not reported: Anorexia

Abacavir, dolutegravir, and/or lamivudine:

-Frequency not reported: Lactic acidosis

-Postmarketing reports: Hyperlactemia, anorexia

Abacavir:

-Frequency not reported: Elevated blood glucose, elevated triglycerides

-Postmarketing reports: Hyperlactatemia, lactic acidosis

Lamivudine:

-Postmarketing reports: Hyperlactatemia, lactic acidosis

Antiretroviral therapy:

-Frequency not reported: Increased glucose levels

Musculoskeletal

Common (1% to 10%): Elevated creatine phosphokinase (CPK), arthralgia

Frequency not reported: Myositis

Rare (0.01% to 0.1%): Rhabdomyolysis

Abacavir, dolutegravir, and/or lamivudine:

-Postmarketing reports: Muscle weakness, elevated CPK, myalgia, rhabdomyolysis

Abacavir:

-Frequency not reported: Elevated CPK

Dolutegravir:

-Frequency not reported: Asymptomatic CPK elevations

-Postmarketing reports: Arthralgia, myalgia

Lamivudine:

-Postmarketing reports: Muscle disorders, arthralgia, rhabdomyolysis

Combination antiretroviral therapy:

-Frequency not reported: Osteonecrosis

Grade 2 and grade 3 to 4 elevations in CPK were reported in up to 5% and up to 7% of therapy-naive patients, respectively. In general, laboratory abnormalities were similar in therapy-experienced patients.

Asymptomatic CPK elevations, mainly associated with exercise, have been reported with dolutegravir.

Hematologic

Grade 2 and grade 3 to 4 reductions in total neutrophils were reported in up to 4% and up to 3% of therapy-naive patients, respectively. In general, laboratory abnormalities were similar in therapy-experienced patients.

Common (1% to 10%): Decreased total neutrophils

Abacavir, dolutegravir, and/or lamivudine:

-Postmarketing reports: Aplastic anemia, anemia (including pure red cell aplasia and severe anemias progressing on therapy), lymphadenopathy, splenomegaly

Abacavir:

-Uncommon (0.1% to 1%): Anemia, neutropenia

-Frequency not reported: Thrombocytopenia, low WBC count

Lamivudine:

-Uncommon (0.1% to 1%): Thrombocytopenia

-Postmarketing reports: Pure red cell aplasia

Dermatologic

Common (1% to 10%): Rash (included rash, generalized rash, macular rash, maculopapular rash, pruritic rash, drug eruption), pruritus, alopecia

Abacavir, dolutegravir, and/or lamivudine:

-Postmarketing reports: Urticaria, alopecia, erythema multiforme

Abacavir:

-Postmarketing reports: Rash (without systemic symptoms), erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis

Lamivudine:

-Postmarketing reports: Alopecia

Suspected Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have been reported in patients using abacavir primarily in combination with agents known to be associated with SJS and TEN, respectively.

Cases of erythema multiforme, SJS, or TEN have been reported very rarely when abacavir hypersensitivity could not be ruled out.

Respiratory

Common (1% to 10%): Cough

Abacavir, dolutegravir, and/or lamivudine:

-Postmarketing reports: Abnormal breath sounds/wheezing, nasal symptoms

Immunologic

Uncommon (0.1% to 1%): Immune reconstitution/reactivation syndrome

Frequency not reported: Autoimmune disorders in the setting of immune reconstitution (e.g., Graves' disease, polymyositis, Guillain-Barre syndrome, autoimmune hepatitis)

Renal

Dolutegravir was shown to increase serum creatinine due to inhibition of tubular secretion of creatinine without affecting renal glomerular function. Increased serum creatinine was reported within the first 4 weeks of therapy and remained stable through 144 weeks. In 1 trial, a mean change from baseline of 0.14 mg/dL (range: -0.25 to 0.81 mg/dL) was reported after 144 weeks of therapy in therapy-naive patients. Creatinine increases were similar in therapy-experienced patients.

Frequency not reported: Renal impairment, increased serum creatinine (due to inhibition of tubular secretion of creatinine)

Cardiovascular

Abacavir:

-Frequency not reported: Myocardial infarction (MI)

Several prospective, observational, epidemiological studies reported an association with the use of abacavir and the risk of MI. Meta-analysis of randomized, controlled clinical trials showed no excess risk of MI in abacavir-treated patients as compared with control subjects. Overall, available data from observational studies and controlled clinical trials showed inconsistency; evidence for causal relationship between abacavir and risk of MI was inconclusive.

Editorial References and Review

Medically reviewed by USARx EDITORIAL TEAM Last updated on 1/1/2020.

Source: Drugs.com Triumeq (www.drugs.com/triumeq.html).